TG Therapeutics Inc (NASDAQ: TGTX) has seen a decline in its stock price by -1.40 in relation to its previous close of 16.42. However, the company has experienced a 20.19% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-05-02 that TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Jenna Bosco – Senior Vice President of Corporate Communications Michael Weiss – President and Chief Executive Officer Adam Waldman – Chief Commercialization Officer Sean Power – Chief Financial Officer Conference Call Participants Michael DiFiore – Evercore ISI Edward White – H.C. Wainwright Roger Song – Jefferies Matthew Kaplan – Ladenburg Thalmann Mayank Mamtani – B.
Is It Worth Investing in TG Therapeutics Inc (NASDAQ: TGTX) Right Now?
The price-to-earnings ratio for TG Therapeutics Inc (NASDAQ: TGTX) is above average at 73.42x. The 36-month beta value for TGTX is also noteworthy at 2.28. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TGTX is 139.77M, and at present, short sellers hold a 25.55% of that float. The average trading volume of TGTX on May 06, 2024 was 3.81M shares.
TGTX’s Market Performance
TGTX stock saw an increase of 20.19% in the past week, with a monthly gain of 11.96% and a quarterly increase of -1.64%. The volatility ratio for the week is 9.29%, and the volatility levels for the last 30 days are 5.53% for TG Therapeutics Inc (TGTX). The simple moving average for the last 20 days is 12.87% for TGTX stock, with a simple moving average of 21.30% for the last 200 days.
Analysts’ Opinion of TGTX
Many brokerage firms have already submitted their reports for TGTX stocks, with Goldman repeating the rating for TGTX by listing it as a “Neutral.” The predicted price for TGTX in the upcoming period, according to Goldman is $12 based on the research report published on August 02, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see TGTX reach a price target of $40, previously predicting the price at $55. The rating they have provided for TGTX stocks is “Buy” according to the report published on June 26th, 2023.
BofA Securities gave a rating of “Underperform” to TGTX, setting the target price at $5 in the report published on May 20th of the previous year.
TGTX Trading at 6.83% from the 50-Day Moving Average
After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.61% of loss for the given period.
Volatility was left at 5.53%, however, over the last 30 days, the volatility rate increased by 9.29%, as shares surge +11.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.46% upper at present.
During the last 5 trading sessions, TGTX rose by +20.19%, which changed the moving average for the period of 200-days by -23.78% in comparison to the 20-day moving average, which settled at $14.43. In addition, TG Therapeutics Inc saw -5.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TGTX starting from Lonial Sagar, who sale 5,000 shares at the price of $15.94 back on Mar 13 ’24. After this action, Lonial Sagar now owns 108,878 shares of TG Therapeutics Inc, valued at $79,675 using the latest closing price.
Charney Laurence N, the Director of TG Therapeutics Inc, sale 22,000 shares at $15.97 during a trade that took place back on Mar 12 ’24, which means that Charney Laurence N is holding 215,229 shares at $351,340 based on the most recent closing price.
Stock Fundamentals for TGTX
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.93 for the gross margin
The net margin for TG Therapeutics Inc stands at 0.14. The total capital return value is set at 0.13. Equity return is now at value 43.93, with 14.44 for asset returns.
Currently, EBITDA for the company is 21.06 million with net debt to EBITDA at 4.42. When we switch over and look at the enterprise to sales, we see a ratio of 9.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.92.
Conclusion
In summary, TG Therapeutics Inc (TGTX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
